Original Source(s)
Related Content
FDA Approves Less Frequent Lebrikizumab Dosing
Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.
June 10, 2026
-
2 min
Mental Health May Impact Dermatologic Quality of Life
Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.
July 9, 2026
-
3 min
Rare Skin Reaction Reported With Tirzepatide
A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.
May 7, 2026
-
3 min